Merck chair looks back over 40-year career at company

As Merck ($MRK) Chairman Richard Clark (photo) prepares to retire, a phillyBurbs profile traces his career at the drugmaker from quality control manager at West Point to the company helm. Report

Suggested Articles

Merck’s Keytruda already boasts an OK in some esophageal cancer patients, but it’s looking to widen its reach in the tough-to-treat disease.

GI cancers are stubborn, as plenty of oncology drugmakers know. But BMS' Opdivo has broken through with two potentially practice-changing trials.

The custodial measure came after Chinese customs officials raided Genscript’s businesses for “suspected violations of import and export regulations.”